UCSF Helen Diller Family Cancer Center
Welcome,         Profile    Billing    Logout  
 10 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hermiston, Michelle
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

Active, not recruiting
2/3
640
US, Canada, RoW
Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma
12/20
12/20
NCT02205762 / 2011-001699-20: LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Recruiting
2/3
1400
US
Prednisone, Vinblastine, Velban®, Vincaleukoblastine Sulfate, mercaptopurine, -Purinethol®, -6-MP, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, Cytarabine, Ara-C, 2-chlorodeoxyadenosine, 2-CdA, Cladribin®, Leustatin®, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin, IVIG
North American Consortium for Histiocytosis, Histiocyte Society
Langerhans Cell Histiocytosis
07/25
07/25
NCT05828069: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
2
48
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Lumbar Puncture, LP, Spinal Tap, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Tovorafenib, BIIB 024, BIIB-024, BIIB024, DAY 101, DAY-101, DAY101, MLN 2480, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK 580, TAK-580, TAK580
National Cancer Institute (NCI)
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
05/25
05/25
IDEAL2, NCT05082519: Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Recruiting
2
240
US
IDEAL2 Intervention
Etan Orgel, Therapeutic Advances in Childhood Leukemia Consortium
B-cell Acute Lymphoblastic Leukemia, Obesity
10/26
10/31
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Active, not recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
E4412, NCT01896999: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Checkmark Results in combination with Opdivo & Adcentris
Dec 2018 - Dec 2018: Results in combination with Opdivo & Adcentris
Active, not recruiting
1/2
146
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
12/26
12/26
NCT04551131: Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting
1/2
62
US
Ruxolitinib, Jakafi®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16
St. Jude Children's Research Hospital, Incyte Corporation, North American Consortium for Histiocytosis, Cures Within Reach
Hemophagocytic Lymphohistiocytosis
08/25
08/26
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Recruiting
1
36
Canada, US, RoW
Marqibo
Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
08/21
12/22
NCT05476770: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting
1
54
US, RoW
Tagraxofusp, Elzonris, Fludarabine, Cytarabine, Cytosar, Dexamethasone, Decadron, Vincristine, Oncovin, Azacitidine, AZA, Vidaza, Methotrexate, MTX, Amethopterin, Cytarabine IT, Hydrocortisone
Therapeutic Advances in Childhood Leukemia Consortium
Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
11/25
11/27
NCT03719105: Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Recruiting
1
40
US
Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
New York Medical College, University of Alabama at Birmingham
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
12/25
12/26
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 

Download Options